Revenue recognition and accounts receivable (Tables)
|
9 Months Ended |
Sep. 30, 2026 |
|---|
| Revenue Recognition And Accounts Receivable [Abstract] |
|
| Schedule of Net Sales by Product Category and Reporting Segment |
The tables below present net sales by product category and reporting segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
Change |
|
Therapeutic Solutions |
|
$ |
63,956 |
|
|
$ |
61,211 |
|
|
|
4.5 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
107,493 |
|
|
|
110,852 |
|
|
|
-3.0 |
% |
Global Spine |
|
|
171,449 |
|
|
|
172,063 |
|
|
|
-0.4 |
% |
Global Limb Reconstruction |
|
|
36,413 |
|
|
|
33,571 |
|
|
|
8.5 |
% |
Net sales |
|
$ |
207,862 |
|
|
$ |
205,634 |
|
|
|
1.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
Change |
|
Therapeutic Solutions |
|
$ |
185,882 |
|
|
$ |
178,834 |
|
|
|
3.9 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
322,662 |
|
|
|
326,889 |
|
|
|
-1.3 |
% |
Global Spine |
|
|
508,544 |
|
|
|
505,723 |
|
|
|
0.6 |
% |
Global Limb Reconstruction |
|
|
106,959 |
|
|
|
96,678 |
|
|
|
10.6 |
% |
Net sales |
|
$ |
615,503 |
|
|
$ |
602,401 |
|
|
|
2.2 |
% |
|
| Schedule of Components Net Sales |
The table below presents product sales and marketing service fees, which are both components of net sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Product sales |
|
$ |
196,990 |
|
|
$ |
193,813 |
|
|
$ |
583,085 |
|
|
$ |
566,841 |
|
Marketing service fees |
|
|
10,872 |
|
|
|
11,821 |
|
|
|
32,418 |
|
|
|
35,560 |
|
Net sales |
|
$ |
207,862 |
|
|
$ |
205,634 |
|
|
$ |
615,503 |
|
|
$ |
602,401 |
|
|
| Allowances for Expected Credit Losses |
The following table provides the detail of changes in the Company's allowance for expected credit losses for the three and nine months ended September 30, 2026, and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Allowance for expected credit losses beginning balance |
|
$ |
10,563 |
|
|
$ |
8,909 |
|
|
$ |
8,308 |
|
|
$ |
7,418 |
|
Current period provision for expected credit losses |
|
|
1,242 |
|
|
|
629 |
|
|
|
4,833 |
|
|
|
2,466 |
|
Write-offs charged against the allowance and other |
|
|
(176 |
) |
|
|
(112 |
) |
|
|
(1,435 |
) |
|
|
(870 |
) |
Effect of changes in foreign exchange rates |
|
|
(46 |
) |
|
|
(13 |
) |
|
|
(123 |
) |
|
|
399 |
|
Allowance for expected credit losses ending balance |
|
$ |
11,583 |
|
|
$ |
9,413 |
|
|
$ |
11,583 |
|
|
$ |
9,413 |
|
|